As an example, comparisons between CD46 and CAR-targeted adenoviral therapy have demonstrated superior outcomes with CD46 targeting in bladder cancer [69] and ovarian cancer [70], despite comparable receptor expression by the tumor cells. This evidence concerns the gene CD46 and urinary bladder carcinoma.